Full-Length Original Research
Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial
Article first published online: 3 OCT 2013
Wiley Periodicals, Inc. © 2013 International League Against Epilepsy
Volume 55, Issue 1, pages 38–46, January 2014
How to Cite
Epilepsia, 55(1):38–46, 2014
- Issue published online: 21 JAN 2014
- Article first published online: 3 OCT 2013
- Manuscript Accepted: 22 AUG 2013
- UCB Pharma
Table S1. Exclusion criteria.
Table S2. Baseline demographic and epilepsy characteristics and concomitant antiepileptic drugs (overall ITT population, ITT focal population, and ITT generalized population).
Table S3. Dose levels of patients during maintenance (ITT population).
Table S4. Psychiatric adverse events in ≥1% of patients in either treatment group during the 16-week treatment period (ITT population).
Table S5. Efficacy analyses over the 16-week treatment period stratified by concomitant levetiracetam use (ITT focal seizure population).
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.